利格列汀联合CSII与单用CSII强化治疗初发2型糖尿病的临床疗效对比

发布时间：2018-08-24 07:41

【摘要】：目的探讨利格列汀联合胰岛素泵持续皮下输注(CSII)与单用CSII对初发2型糖尿病(T2DM)患者各临床指标的影响。方法新发T2DM患者130例。最终完成随访的对照组和观察组各58例。观察组给予利格列汀5 mg/d,联合CSII治疗,对照组单用CSII治疗,根据血糖情况治疗10~14 d后患者血糖达标,胰岛素剂量逐渐减至0 U出院。对照组生活因素干预,观察组继续应用利格列汀治疗。治疗前、治疗后4、12 w均测定体重指数(BMI)、空腹血糖(FPG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(Hb A1c)、C肽、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)等指标,计算胰岛素敏感指数、胰岛素抵抗指数;出院时记录患者住院天数及治疗费用。结果治疗前后两组BMI无明显差异(P0.05)。治疗后4、12 w FPG、2 h PG、Hb A1c、胰岛素抵抗指数、TG、TC、LDL-C均较基线水平显著下降(P0.05),胰岛素敏感指数较基线升高(P0.05)。观察组比对照组各项指标改善更明显(P0.05),观察组住院天数及费用比对照组明显下降(P0.01)。结论对于初诊T2DM患者,利格列汀联合CSII与单独CSII相比能更好地控制患者血糖水平,改善胰岛素抵抗,恢复胰岛功能,降低血脂,缩短住院时间和费用。
[Abstract]:Objective to investigate the effect of riglitatin combined with continuous subcutaneous infusion of insulin pump (CSII) and CSII alone on the clinical parameters of patients with type 2 diabetes mellitus (T2DM). Methods 130 new T2DM patients were treated. There were 58 cases in the control group and 58 cases in the observation group. The observation group was treated with riglitatin 5 mg/d, combined with CSII, while the control group was treated with CSII alone. After 10 ~ 14 days of blood glucose treatment, the blood glucose was up to standard, and the insulin dose was gradually reduced to 0 U. The intervention of life factors in the control group and the treatment of riglitatin were continued in the observation group. Body mass index (BMI), fasting blood glucose (FPG),) 2 h postprandial blood glucose (2 h PG), glycosylated hemoglobin (Hb A1c) C peptide), triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) were measured before and 4 weeks after treatment, and insulin sensitivity index was calculated. Insulin resistance index, hospitalization days and treatment cost were recorded at discharge. Results there was no significant difference in BMI between the two groups before and after treatment (P0.05). After 4 weeks of treatment, FPG,2 h PG,Hb A1c, insulin resistance index (TGG) TCU LDL-C decreased significantly compared with baseline level (P0.05), insulin sensitivity index (ISI) increased compared with baseline level (P0.05). Compared with the control group, the indexes of the observation group improved significantly (P0.05), the days of hospitalization and the cost of the observation group were significantly lower than that of the control group (P0.01). Conclusion for the newly diagnosed T2DM patients, riglitatin combined with CSII can better control the blood glucose level, improve insulin resistance, restore pancreatic islet function, reduce blood lipids, and shorten hospitalization time and cost compared with CSII alone.
【作者单位】：吉林大学第二医院内分泌科;
【基金】：吉林省科技发展计划项目(No.20160101103JC)
【分类号】：R587.1

【参考文献】